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Key Points
• Life-threatening hemor-
rhage during the course
of childbirth is pre-
ceded by low fibrinogen
and prolonged aPTT
soon after its onset.
• Assessment of fibrino-
gen and aPTT during
early postpartum hem-
orrhage may help to
prevent progression
to uncontrollable blood
loss.
We describe the pattern of change in coagulation parameters during the course of severe
postpartum hemorrhage in a retrospective cohort study among 1312 women experiencing
severe postpartum hemorrhage necessitating blood transfusion. Levels of hemoglobin,
hematocrit, platelet count, ﬁbrinogen, activated partial thromboplastin time (aPTT) and
prothrombin time (PT) per categorized volume of blood loss during severe postpartum
hemorrhagewere described and compared betweenwomenwith andwithout the composite
adverse outcome. Need for surgical intervention, severe acute maternal morbidity, and
maternal mortality were jointly considered the composite adverse outcome. Of the 1312
women, 463 (35%) developed the composite adverse outcome. The incidence of a ﬁbrinogen
level,2 g/L was 26% (342 per 1312). Low ﬁbrinogen and prolonged aPTT during the ﬁrst 2 L
of hemorrhage were associated with a subsequent composite adverse outcome; median
ﬁbrinogen and aPTT amongwomenwith andwithout the composite end point after 1.5 to 2 L
of hemorrhage were 1.5 g/L (interquartile range [IQR], 1.0-1.9) vs 2.7 g/L (IQR, 1.9-3.4)
and 39 s (IQR, 30-47) vs 32 s (IQR, 28-36), respectively. PT and platelet count as assessed
during the ﬁrst 2 L of hemorrhage were not associated with morbidity or mortality. Our
results suggest that detection of low levels of ﬁbrinogen and elevated aPTT levels during
early postpartum hemorrhage can contribute to the identiﬁcation of women that may
beneﬁt from targeted hemostatic treatment. Essential in this identiﬁcation process is
the moment of reaching a level of ﬁbrinogen of ,2 g/L during the course of postpartum
hemorrhage.
Introduction
Postpartum hemorrhage is a major cause of maternal morbidity and mortality with an incidence that
seems to be increasing over the last decade.1-8
Efforts to prevent morbidity and mortality because of postpartum hemorrhage focus among other things
on laboratory monitoring of hemostasis in order to enable timely treatment of possible coagulopathy.
Hemostasis may be monitored by laboratory-based prothrombin time (PT)/activated partial thrombo-
plastin time (aPTT), Clauss fibrinogen, platelet count, and point of care testing.9 Experts recommend that
all these may be used simultaneously because there is currently no high level evidence on the best
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strategy.9 This advice leads to inefficiency, waste, and considerable
variation in the care for patients with postpartum hemorrhage.
In order to determine the optimal strategy to monitor coagulopathy, it
is crucial to know the patterns of changes in coagulation parameters
in relation to the phases of postpartum hemorrhage and to identify
which parameters show the fastest changes associated with the risk
of severe maternal outcomes. Data on the change in coagulation
parameters during the course of postpartum hemorrhage, thus per
liter of ongoing hemorrhage, are limited. Earlier studies used repeated
measurements at set time points or reported worst values in the
course of bleeding.10-12 Some have suggested that low fibrinogen
concentration might be the earliest predictor of progression toward
severe postpartum hemorrhage.11,13,14 Investigators studying
women with severe postpartum hemorrhage face the enormous
challenge of including women in a life-threatening condition, frequently
leading to failure to include the most severe cases.
Diligent observation of present-day monitoring of hemostasis and
outcomes among an unselected cohort of women with ongoing
postpartum hemorrhagemay help to identify the hemostasis parameters
that are able to recognize women with a high risk for morbidity and
mortality as early as possible during postpartum hemorrhage.
The aim of this study was to describe coagulation parameters
including fibrinogen during the course of severe postpartum
hemorrhage per categorized volume of blood loss. Also, co-
agulation parameters during early postpartum hemorrhage were
compared between women with and without severe acute maternal
morbidity, mortality, and need for surgical intervention.
Methods
Design and study population
The Transfusion Strategies in Women during Major Obstetric
Hemorrhage-1 (TeMpOH-1) study is a nationwide retrospective
cohort study in 61 hospitals in The Netherlands. TeMpOH-1
included women who received at least 4 units of red cells or any
transfusion of fresh frozen plasma (FFP) and/or platelets in addition
to red cells because of severe obstetric hemorrhage ($1000 mL
blood loss during pregnancy, birth, or puerperium). For the present
analysis, we selected women from the TeMpOH-1 cohort who met
criteria for primary postpartum hemorrhage (blood loss $1000 mL
occurring within the first 24 hours after childbirth). We excluded
women for whom we did not have any coagulation parameter
measured between childbirth and end of active postpartum
hemorrhage. Women 18 years of age and older who met the
inclusion criteria were selected. Women with a known coagulation
disorder or anticoagulant were included in the study. Approval for
the TeMpOH-1 study was obtained from the Medical Ethical
Research Committee of the Leiden University Medical Centre
(P12.273) and from the institutional review board of each
participating hospital. The study was registered in the Netherlands
Trial Register (NTR4079). Detailed design of the study has been
reported elsewhere.15 Because of the retrospective design of the
study, the need to obtain informed consent from eligible women
was waived by the ethics committee. Eligible women were selected
from transfusion databases and birth registries of participating
hospitals with 191 772 births between 2011 and 2013. By cross-
referencing electronic data from the hospitals’ blood transfusion
services with local birth registers in participating hospitals, all
women experiencing severe postpartum hemorrhage necessitating
blood transfusion during the inclusion period of the study could be
included. In most hospitals, no pregnancy-specific massive trans-
fusion protocol is available, and in most cases, the normal
(nonpregnancy) target values for hemostatic therapy are used:
hemoglobin (Hb), 8 g/dL; PT and aPTT ,1.53 prolonged; platelet
count .50 3 109/L to 100 3 109/L; and fibrinogen .1.5 g/L.
Data collection
Detailed information on maternal, pregnancy, and birth character-
istics was collected from medical files. Chart reviews were
conducted by trained medical students and research nurses. Data
were recorded from files available at the maternity ward, operating
theater, and intensive care unit for the following parameters:
maternal age at the time of birth, parity, maternal body weight
during early pregnancy, maternal height, ethnicity, gestational
age, obstetric history, mode of birth, cause of major obstetric
hemorrhage, abnormal placentation, shock, timing and volume of
fluids and blood products administered, timing of surgical and
hemostatic interventions, and consecutive measurements of blood
loss until cessation of bleeding. Blood loss was measured by
weighing gauzes and other soaked materials and by use of a
collector bag and suction system in the operating theater.
Laboratory parameters
Of the included women, we documented available laboratory
parameters and data on type and volume as well as timing of clear
fluids and blood products administered during the course of
postpartum hemorrhage, Hb level (g/dL), hematocrit (Ht; fraction),
platelet count (3109/L), aPTT (seconds), PT (seconds), and
fibrinogen (g/L). Laboratory parameters from the first measurement
of blood loss onward were considered, including parameters drawn
from women before they had reached 1000 mL of blood loss.
Unlikely values were verified in the medical records. There was no
preset protocol for obtaining specimens: blood samples during
postpartum hemorrhage had been obtained on request of the
caregiver leading to different numbers and panels of results of
laboratory parameters.
Composite adverse maternal outcome
Emergency peripartum hysterectomy, ligation of the uterine arteries,
B-lynch suture (in The Netherlands only used as emergency
procedure), arterial embolization, or admission into an intensive
care unit were jointly considered the combined end point of severe
acute maternal morbidity. Women were compared with regard to
whether they had developed a composite adverse maternal
outcome consisting of severe acute maternal morbidity, maternal
mortality, or need for surgical intervention.
Statistical analyses
Coagulation parameters are presented as median and interquartile
ranges (IQRs) because of non-Gaussian distribution. The phases of
ongoing postpartum hemorrhage were categorized according to
increasing volumes of blood loss: 0 to 1 L, 1 to 1.5 L, 1.5 to 2 L, 2 to
2.5 L, 2.5 to 3 L, 3 to 3.5 L, 3.5 to 4 L, and .4 L. Each laboratory
parameter result was assigned to the category of blood loss at
which the respective blood sample had been taken. In case of
multiple measurements per woman within 1 category of volume of
blood loss, the mean of those values was used. In order to assign
a volume of blood loss for each of the laboratory parameters,
we imputed volumes of blood loss using linear interpolation of
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2 consecutive blood volume measurements. In case total blood loss
was the only available data point, or the blood sample was drawn
before the first measurement of blood loss volume, the birth time of
the baby was used as the starting point for the interpolation. Levels
of coagulation parameters between groups were compared with
Mann-Whitney U tests. Reference ranges of aPTT varied some-
what for the 61 participating hospitals as a result of use of different
types of reagents. To examine the robustness of aPTT results, we
repeated the analyses using aPTT ratios, which were calculated by
dividing the observed aPTT levels by the mean of the hospital
specific reference range.
Results
Patient characteristics
Over the 2-year inclusion period of the TeMpOH-1 study, 1391
women had received at least 4 units of red cells or FFP or platelets
in addition to red cells for postpartum hemorrhage. A total of 1312
women with primary postpartum hemorrhage had at least 1 valid
measurement of coagulation parameters sampled during active
bleeding (Figure 1). The median volume of blood loss among these
1312 women was 3 L (IQR, 2.5-4.0). Characteristics of the study
population and of women with and without the composite adverse
outcome are reported in Table 1.
Laboratory parameters during
postpartum hemorrhage
Hb concentration was measured on 2605 occasions, Ht on 2245
occasions, platelet count on 1581 occasions, fibrinogen concen-
tration on 775 occasions, PT on 876 occasions, and aPTT on 1075
occasions. Women had a median amount of 3 (IQR, 2-5) blood loss
measurements during active postpartum hemorrhage. Figure 2
shows results of the laboratory test results according to increasing
volumes of hemorrhage. The accompanying patient count, mean,
standard deviation, median, IQR, and lowest and highest values of
laboratory parameters according to increasing volumes of blood
loss are presented in supplemental Table 1. Levels of Hb tended to
decrease up to 2.0 to 2.5 L of blood loss to an Hb level of 7.7 g/dL
(IQR, 6.4-9.0) and an Ht of 0.24 (IQR, 0.20-0.28), after which
stabilization occurred. At 2.5 L of blood loss, 203 out of 443 (46%)
women had been transfused with blood products.
Platelet counts also decreased with increasing volume of blood loss.
Women with 2.0 to 2.5 L of blood loss had a median platelet count of
1463 109/L (IQR, 108-186). Four percent (10/253) of these women
had received a platelet transfusion at that time. For 128 women with
blood loss of 3.5 to 4.0 L the median platelet count was 1153 109/L
(IQR, 89-143); 21 of these 128 (16%) women had received platelet
transfusions, and 113/128 (88%) had received a blood product.
There were 342 (0.18% of all births in the 61 hospitals and 26% of
the women in our study cohort) women who developed a fibrinogen
level below 2 g/L. A fibrinogen level below 1 g/L was reached by
78 women. Five percent (70/1312) of the women in our cohort
reached a fibrinogen level below 2 g/L after losing ,2 L of blood.
Four women reached this level because of postpartum hemorrhage
because of placental abruption. Median baseline fibrinogen level
during early postpartum hemorrhage was 2.8 g/L (IQR, 1.6-4.3).
Fibrinogen levels tended to decrease up to 2 to 2.5 L of blood loss
at 2.1 g/L (IQR, 1.6-2.7). Among 152 women who had lost .4 L,
median level of fibrinogen was 1.8 g/L (IQR, 1.4-2.2); 41% of these
women had been treated with fibrinogen concentrates. In the
subgroup of patients with postpartum hemorrhage because of
uterine atony or retained placenta, we observed a similar trend
(supplemental Figure 4).
Median PT values showed a slight increase with increasing
volumes of blood loss. During the earliest phase of postpartum
hemorrhage, median PT was 12.7 seconds (IQR, 10.7-15.9);
among women who lost .4 L, the median PT was 14.9 (IQR,
12.0-17.5). Median aPTT increased with increasing volumes of
blood loss from 30.0 seconds (IQR, 27.0-35.0) during early
bleeding to 37.5 seconds (IQR, 32.0-43.6) in the maximum blood
loss category. Sensitivity analyses on the aPTT ratio showed
similar results (supplemental Figure 5).
Laboratory parameters and adverse
maternal outcome
Of the 1312 women, 463 (35%) developed a combined end point
of severe acute maternal morbidity, mortality, or the need for
Women giving birth in 61 participating
hospitals in The Netherlands
from 2011 to 2013
N= 191.772
Cross-referencing
data of hospitals’
blood transfusion
services with local
birth registers
Women with severe postpartum
hemorrhage 1000mL who received
4 units of red cells or any transfusion of
FFP or platelets in addition to red cells
n= 1391 (0.73%)
4 RBC
918(66%)
1-3 RBC
+ FFP
463 (33%)
1-3 RBC
+ platelets
10 (1%)
79 women excluded
due to no valid
laboratory
measurement during
active bleeding
Final sample
n= 1312 (0.68%)
4 RBC
875(67%)
1-3 RBC
+ FFP
427 (33%)
1-3 RBC
+ platelets
10 (1%)
Figure 1. Inclusion flowchart for “Coagulation Parameters during the
Course of Severe Postpartum Hemorrhage: A Nationwide Retrospective
Cohort Study.”
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surgical intervention; 37% (172/463 women) of these women
developed .1 of the items composing the combined adverse end
point. To arrest bleeding, hysterectomy was necessary in 72 (5%)
women, 164 (13%) were treated with arterial embolization, and in
46 (4%) women an emergency B-lynch procedure or ligation of
arteries was performed. Of the women in our study cohort, 386
(29%) were admitted to the intensive care unit and 7 (0.5%) died as
a result of severe hemorrhage. Figure 3 shows laboratory results
during postpartum hemorrhage of women with and women without
the composite adverse outcome. Women who developed the
composite adverse outcome had lower fibrinogen concentra-
tions and longer aPTTs than women who did not develop the end
point, which was already apparent and most pronounced during
the earliest phases of postpartum hemorrhage. There were no
noteworthy differences in Hb, Ht, PT, and platelet levels during the
early phases of postpartum hemorrhage (blood loss ,2 L; Table 2).
Women who developed the composite adverse outcome had a
median fibrinogen level of ,2g/L at 1.5 to 2 L of blood loss,
Table 1. Patient and treatment characteristics of the total study population and according to the development of the composite adverse
outcome
Patient and treatment characteristics Total
Severe acute maternal morbidity, mortality,
and need for surgical intervention
No Yes
Patients, n (%) 1312 849 (65) 463 (35)
Maternal characteristics
Age, y 31.3 (28-35) 31.0 (28-35) 32.0 (29-35)
Body mass index, kg/m2 23.3 (21-26.4) 23.1 (20.9-26.3) 23.5 (21-27)
Ethnicity, white, % 71 75 65
Nulliparity, % 52 54 47
Gestational age, wk 39.6 (38-40.7) 39.7 (38.3-40.9) 39.4 (37.4-40.6)
Mode of birth, %
Caesarean section 25 19 36
Vaginal 75 81 63
Comorbidity, %
Preeclampsia/HELLP 11 9 14
Anticoagulant use 0.5 0.5 0.7
Transfer to hospital, %
Transfer to hospital during labor 14 15 12
Postpartum transfer (birth at home) 12 15 8
Primary cause of bleeding, %
Uterine atony 65 66 63
Retained placenta 17 21 10
Pathological ingrowth of placenta 8 6 12
Placenta previa 1 1 2
Surgical bleeding 7 5 10
Placental abruption 2 2 2
Coagulopathy 1 0 1
Fibrinogen administered, % 10 4 21
Tranexamic acid administered, % 44 36 59
Recombinant FVIIa-administered, % 3 0.1 8
Bleeding rate, mL/min* 2.4 (1.2-4.6) 2.3 (1.2-4.2) 2.4 (1.3-5.3)
Shock (systolic blood pressure,90 or heart rate.120), % 85 84 86
Total volume of clear fluids, L 2.5 (1.7-4.0) 2.5 (1.5-3.5) 3.0 (2.0-4.5)
Total units of blood products 6.0 (4.0-8.0) 5.0 (4.0-6.0) 10.0 (6.0-16.0)
Four or more red cells units, n (%) 875 (67) 481 (57) 394 (85)
One to 3 red cells and 1 or more plasma units, n (%) 427 (33) 360 (42) 67 (14)
One to 3 red cells and 1 or more platelets units, n (%) 10 (1) 8 (1) 2 (0.4)
Total volume of blood loss, L 3.0 (2.5-4.0) 2.8 (2.2-3.3) 4.0 (3.0-5.5)
Values are median (IQR), except as noted.
*Maximum.
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whereas women without the composite adverse outcome had a
median fibrinogen of ,2 g/L after a volume of .3.5 L of blood
loss. Additional results based on first sample during postpartum
hemorrhage irrespective of blood loss volume and receiver-
operating characteristic analyses of progression to the severe
morbidity end point based on the first blood test are provided in
supplemental Tables 2 and 3. Sensitivity analyses with the aPTT
ratio showed similar results (supplemental Table 6). Patient
characteristics of the women with fibrinogen measurements are
also presented (supplemental Table 7).
Discussion
Among women with severe postpartum hemorrhage requiring
blood transfusion, the occurrence of low levels of fibrinogen and
prolonged aPTTs in the earliest phases of hemorrhage was associated
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Figure 2. Coagulation parameters of women during the course of severe postpartum hemorrhage per categorized amount of blood loss. (A) Hemoglobin, (B)
hematocrit, (C) platelet count, (D) fibrinogen, (E) aPTT, and (F) PT. Laboratory parameters are presented in box plots. Circles are outliers. The box represents the 25th and
75th percentiles, and the whiskers are the upper and lower adjacent values.
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with progression toward severe acute maternal morbidity, mortality, or
need for surgical intervention.
Strength and limitations of this study
Our study describes coagulation parameters and morbidity of
women with severe postpartum hemorrhage. The results are
therefore only generalizable to women suffering severe postpartum
hemorrhage. The unique strength of this retrospective study is that
we were able to include all women with severe postpartum
hemorrhage necessitating blood transfusion that had occurred in
the 61 participating hospitals during the study period, including the
most severe cases, enabling reliable and generalizable estimation
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Figure 3. Coagulation parameters of women with and without combined end point of severe acute maternal morbidity or mortality per categorized amount
of blood loss. (A) Hemoglobin, (B) hematocrit, (C) platelet count, (D) fibrinogen, (E) aPTT, and (F) PT. Box plots of coagulation parameters per categorized amount of blood loss
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of percentages of women with coagulopathy during the course of
postpartum hemorrhage. In addition, the large sample size allowed
us to examine patterns of laboratory parameters throughout the
course of ongoing postpartum hemorrhage. The retrospective study
design also has limitations. We did not have control over the
number and specific panels of coagulation samples. Therefore,
our results are based on different selections of women in the
categories of blood loss. Obviously, more blood samples were
drawn from women with more severe bleeding. It is therefore
possible that women with low fibrinogen or prolonged aPTT were
missed in women with lower blood loss as these parameters were
not measured, because there were no measurements. This may
have led to an underestimation of the occurrence of abnormal
laboratory parameters. Moreover, laboratory measurements were
performed in local laboratories of the 61 hospitals, leading to
significant variation in measurements and possible misclassifi-
cation. Such variation will also influence the results toward
underestimation of the strength of the association of coagulation
parameter abnormalities with morbidity and mortality. To be
certain of the accuracy of all low fibrinogen values in our study
cohort, we returned to the 61 participating hospitals and verified all
values of fibrinogen with a level ,2 g/L (and all other outliers
of laboratory parameters) in the medical files. During the
inclusion period of our study, none of the participating hospitals
used thromboelastometry in women experiencing postpartum
hemorrhage.
Comparison with other studies
The occurrence of coagulopathy in postpartum hemorrhage and its
association with maternal morbidity and mortality has been studied
previously. For a correct interpretation of the results of this study in
the context of previous studies, it should be taken into account that
our study differs from previous studies with regard to its source
population: as opposed to previous studies, only women with
severe postpartum hemorrhage necessitating the administration
of blood products were included. Fibrinogen levels of lower than
2 g/L were strongly associated with progression toward severe
postpartum hemorrhage in a study among 128 women with
postpartum hemorrhage.11 However, in this study measurements
were done at predefined hours after enrollment, and information on
the corresponding amount of blood loss at the time of the
measurements was lacking. It therefore remained unclear whether
the level of fibrinogen was a predictor of progression toward more
severe bleeding or a result of blood loss at time of blood sampling.
Another study among 456 women with postpartum hemorrhage
from a large UK unit reported results of Hb, platelet count, PT, and
aPTT tests that were categorized based on the worst value of the
total amount of blood loss at the end of bleeding.10 Fibrinogen was
found to be the parameter that best correlated with increasing
volume of hemorrhage. PT and aPTT remained within the normal
range in most women despite large bleeds. In a review article, Collis
et al summarized results of 5 studies that tried to determine a value
of fibrinogen that could serve as a biomarker for progression of
postpartum hemorrhage.14 These values varied between studies:
fibrinogen level 3.3/3.4/1.8/3.1/2.8 g/L.10,11,13,16,17 Their overall
conclusion was that a fibrinogen level of ,3 g/L and, in particular,
,2 g/L was associated with progression toward more severe
postpartum hemorrhage.
Another study on women in need of massive transfusion because
of postpartum hemorrhage ($8 units of red cells within 24 hours
of delivery) was also based on the first and worst values measured,
regardless of volume of blood loss at sampling.12 Also, in this
study a difference was made between levels of coagulation
parameters for different primary causes of bleeding. Because
the primary cause of bleeding often remains unclear during
active postpartum hemorrhage, and in some cases is only
clarified when additional tests have been performed after the
event, we find it of great clinical importance to study the
pattern of change of coagulation parameters over time in
relation to volume of blood loss, regardless of primary cause of
bleeding.
In our cohort, we observe a higher occurrence of a fibrinogen
concentration below 2 g/L compared with results suggested in
randomized trials. This can be explained by differences in patient
selection. In a Danish multicenter double-blind randomized trial,
women experiencing severe postpartum hemorrhage were treated
with a dose of 2 g of fibrinogen concentrate or placebo.18 Of the
244 randomized women, only 5 had a fibrinogen value ,2 (mean
value in both groups 4.5). A more recent trial randomized 55 women
at a FIBTEM value of 15 mm (considered to be the equivalent to
Table 2. Coagulation parameters during the course of postpartum hemorrhage of women with and without composite adverse
maternal outcome
Blood loss category, L
Hb, g/dL Ht (fraction) Platelet count, 3109/L Fibrinogen, g/L aPTT, s PT, s
Composite end point Composite end point Composite end point Composite end point Composite end point Compositeendpoint
No Yes P* No Yes P* No Yes P* No Yes P* No Yes P* No Yes P*
0.00 to 1.0 10.1 9.7 0.28 0.31 0.29 0.23 178 154 0.24 3.9 2.5 0.09 29 32 0.11 11 13 0.26
1.01 to 1.5 9.3 9.0 0.04 0.28 0.27 0.04 170 156 0.29 3.2 2.3 0.01 30 33 0.03 13 14 0.44
1.51 to 2.0 8.2 8.2 0.91 0.25 0.24 0.84 147 144 0.47 2.7 1.5 ,0.01 32 39 ,0.01 14 14 0.26
2.01 to 2.5 7.7 7.7 0.61 0.24 0.24 0.55 150 142 0.32 2.1 2.0 0.19 33 37 ,0.01 15 14 0.54
2.51 to 3.0 7.9 7.6 0.29 0.24 0.23 0.13 136 119 0.19 2.0 1.8 ,0.01 33 38 ,0.01 14 14 0.42
3.01 to 3.5 7.7 8.4 0.01 0.24 0.25 0.02 117 111 0.21 2.2 2.0 0.40 33 36 0.04 15 14 0.82
3.51 to 4.0 8.3 8.2 0.58 0.25 0.24 0.22 128 110 0.06 2.0 1.7 0.05 34 36 0.09 15 14 0.09
4.01 or more 8.2 8.4 0.06 0.24 0.25 0.04 115 93 ,0.01 1.7 1.8 0.76 34 38 ,0.01 15 15 0.93
*Mann-Whitney U test.
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Clauss fibrinogen value of 3 g/L) to fibrinogen concentrate or
placebo.19 No improvement in outcome was observed in women
who were administered fibrinogen; only 7 women (out of a cohort of
663 women with postpartum hemorrhage) developed a fibrinogen
level below 2 g/L confirming, as discussed by the authors, the
challenges related to consenting women with severe bleeding and
undertaking trial procedures while treating acutely ill women. This
challenge was also experienced by a Finnish research group that
aimed to perform a randomized controlled trial comparing pro-
thrombin complex concentrate and fibrinogen concentrate to FFP
as a treatment of women experiencing postpartum hemorrhage
exceeding 2 L (#NCT01910675). Obtaining informed consent in
an acute situation with severe bleeding turned out to be impossible
(Jouni Ahonen, Helsiniki University, e-mail communication, 15 April
2018).
The results of the TeMpOH-1 study confirm the results of
previous studies on this subject, however, with 1 very important
addendum for acute clinical decision making: the dimension of
time. We found 342 women with a fibrinogen level #2 g/L and a
further 78 women with a fibrinogen level #1 g/L. We have
elucidated that women who experienced postpartum hemor-
rhage without developing a composite outcome of maternal
morbidity and mortality only sporadically reached a fibrinogen
value of ,2 g/L (blood loss .3.5 L). Women who did
develop the composite adverse outcome reached this low
fibrinogen level much earlier (1.5-2 L of blood loss) during
postpartum hemorrhage. This difference in the moment of
reaching a level of fibrinogen of ,2 g/L during the course of
postpartum hemorrhage is essential for the selection of the right
target population for future studies into the potential benefit of
administering fibrinogen concentrate.
Clinical implications
By the timely detection of changes in levels of relevant coagulation
parameters, targeted hemostatic therapy to restore deficiencies
could be administered. However, assessment of fibrinogen levels by
a standard coagulation test like the Clauss fibrinogen assay has a
turnaround time of up to 60 minutes making it unsuitable for acute
clinical decision making.20 Point-of-care devices like ROTEM
thromboelastometry are able to detect essential changes in the
coagulation system within 10 minutes after blood sampling.21
ROTEM FIBTEM could potentially be a worthwhile addition to
postpartum hemorrhage management.22,23 To make progress in
this field, we need to monitor women experiencing postpartum
hemorrhage closely during the process of active blood loss. In our
next currently ongoing study (#NCT02149472), we will further
elucidate the predictive value of early changes in coagulation
parameters (including thromboelastometry) for the development of
severe acute maternal morbidity and mortality in women experienc-
ing postpartum hemorrhage. The results provided by this study
provide a solid knowledge base to be used when making the
transition toward the evidence-based use of rapid point-of-care
testing.
Conclusion
In this nationwide retrospective cohort study on the change of
coagulation parameters in 1312 women experiencing severe
postpartum hemorrhage requiring blood transfusion, we provide a
solid knowledge base of common patterns of change in coagulation
parameters during postpartum hemorrhage. Our results suggest
that detection of low levels of fibrinogen and elevated aPTT levels
during early postpartum hemorrhage can contribute to the
identification of women that may benefit from targeted hemostatic
treatment. Based on these results, we advise to assess levels of
fibrinogen and aPTT in all women who experience postpartum
hemorrhage with blood loss exceeding 1 L.
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